Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NGM BIOPHARMACEUTICALS INC (NGM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights"
02/28/2023 8-K Quarterly results
Docs: "NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
Docs: "NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results"
03/01/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Completed enrollment in Phase 2b ALPINE 2/3 study of aldafermin in NASH patients. NGM completed enrollment in the Phase 2b ALPINE 2/3 clinical study of aldafermin in patients with biopsy-confirmed NASH and stage 2 or 3 liver fibrosis. The 24-week study will assess the efficacy, safety and tolerability of 0.3 mg, 1 mg and 3 mg doses of aldafermin compared to placebo. The primary objective of the ALPINE 2/3 study is to evaluate a dose response showing an improvement in liver fibrosis by ≥ 1stage with no worsening of steatohepatitis at week 24. NGM expects to report topline findings from the study in the second quarter of 2021. • Ongoing enrollment in Phase 2b ALPINE 4 study of aldafermin in NASH patients with compensated cirrhosis. NGM continued enrollment in the Phase 2b ALPINE..."
08/12/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "Initiated Phase 2b ALPINE 4 study of aldafermin in compensated NASH cirrhosis . In March 2020, NGM dosed the first patient in the dose-ranging ALPINE 4 study to evaluate the safety and efficacy of aldafermin versus placebo in patients with biopsy-confirmed NASH cirrhosis. The primary efficacy objective is to evaluate the treatment effect on histology, defined as fibrosis regression of at least one stage without worsening of NASH. This global, multi-center study is expected to enroll approximately 150 patients who will be dosed with 0.3 mg, 1 mg, 3 mg of aldafermin or placebo for 48 weeks. Aldafermin is wholly-owned by NGM. “We are pleased to have initiated our Phase 2b ALPINE 4 clinical study and thrilled we have achieved this significant milestone, marking our first study in F4 NASH patie..."
03/17/2020 8-K Quarterly results
08/12/2019 8-K Quarterly results
Docs: "Completed enrollment of Cohort 4 of the Phase 2 clinical study of NGM282 in non-alcoholic steatohepatitis patients with F2-F3 fibrosis. Cohort 4 has enrolled 78 patients with biopsy-confirmed NASH and stage F2-F3 liver fibrosis and will assess the efficacy, safety and tolerability of aldafermin 1 mg compared to placebo. An interim analysis of the non-invasive measures of efficacy, including liver fat content as measured by MRI-PDFF, liver transaminases and exploratory fibrosis biomarkers, will be conducted in approximately half the subjects after 24 weeks of treatment. NGM expects to report these interim data in the fourth quarter of 2019. Topline results of the full Cohort 4, which will include an assessment of the effect of 24 weeks of treatment on liver histology, are anticipated in ear..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy